A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients
Edward A. Stadtmauer(University of Pennsylvania), Elchonon M. Berkowitz(GlaxoSmithKline (United States)), Francis K. Buadi, Sherif B. Mossad(Cleveland Clinic), Keith M. Sullivan(National Cancer Institute), Sanjeet Dadwal(City Of Hope National Medical Center), Jo‐Anne H. Young(University of Minnesota System), Charalambos Andreadis(University of California, San Francisco), Genovefa A. Papanicolaou(Memorial Sloan Kettering Cancer Center), Mohamed El Idrissi(GlaxoSmithKline (Belgium)), Thomas C. Heineman(GlaxoSmithKline (United States)), Thomas C. Shea(University of North Carolina at Chapel Hill), Francisco M. Marty(Brigham and Women's Hospital)
Cited by 177
Related Papers
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America
|Clinical Infectious Diseases|2016|2.8k
Chronic graft-versus-host syndrome in man
|The American Journal of Medicine|1980|2.4k
Methotrexate and Cyclosporine Compared with Cyclosporine Alone for Prophylaxis of Acute Graft versus Host Disease after Marrow Transplantation for Leukemia
|New England Journal of Medicine|1986|1.5k
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
|New England Journal of Medicine|2017|1.2k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.1k